Last update:

Parkinson's & Movement disorders news

Parkinson's & Movement disorders

Insight into protein misfolding could open up new approaches to treat Parkinson's disease

Researchers have uncovered a link between the structure of the protein alpha-synuclein and its likelihood to misfold and aggregate.

Parkinson's & Movement disorders

Growth factors and Parkinson's disease—Where next?

Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson's disease (PD), but trials have been disappointing. A panel of prominent leaders ...

Parkinson's & Movement disorders

Parkinson's dyskinesia mechanism explained

Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication. The mechanism underlying this unwanted side effect has ...

Neuroscience

Researchers unravel protein mystery of three brain diseases

The accumulation of one particular protein in the brain is the basis of three very different age-related conditions. Until recently, nobody understood how this was possible. Research by the Laboratory for Neurobiology and ...

Genetics

Parkinson's disease may start in the gut

Researchers at Karolinska Institutet in Sweden and the University of North Carolina in the USA have mapped out the cell types behind various brain disorders. The findings are published in Nature Genetics and offer a roadmap ...

Psychology & Psychiatry

Phone-based therapy beneficial for depression in Parkinson's disease

Telephone-based cognitive behavioral therapy (T-CBT) seems to be an effective intervention for depression in Parkinson disease (PD), outperforming treatment-as-usual (TAU) on all depression, anxiety, and quality-of-life measures, ...

Parkinson's & Movement disorders

Long-term use of isradipine does not slow Parkinson's progression

Long-term treatment with immediate-release isradipine does not seem to slow the clinical progression of early-stage Parkinson's disease. Findings from a multicenter, randomized, parallel-group, double-blind, placebo-controlled ...